NCT00647296 (CL201) is a Phase 2 clinical trial of Dexpramipexole 50 mg/day in Amyotrophic Lateral Sclerosis, sponsored by Knopp Biosciences.

Who is sponsoring NCT00647296?

NCT00647296 is sponsored by Knopp Biosciences.

What drugs are being tested in NCT00647296?

Interventions in NCT00647296: Placebo, Dexpramipexole 50 mg/day, Dexpramipexole 150 mg/day, Dexpramipexole 300 mg/day.

What condition does NCT00647296 study?

NCT00647296 studies Amyotrophic Lateral Sclerosis.

Is NCT00647296 still recruiting?

NCT00647296 is currently completed. Last updated 8 July 2021.

Are results published for NCT00647296?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2021-07-08 · How we verify

NCT00647296: CL201

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety and Tolerability Study of KNS-760704 in Amyotrophic Lateral Sclerosis (ALS)

Completed Phase 2 Results posted Last updated 8 July 2021

What this trial tests

Phase 2 trial testing Placebo in Amyotrophic Lateral Sclerosis in 194 participants. Completed in 4 September 2009.

Timeline

9 April 2008

Primary endpoint
31 July 2009

4 September 2009

Quick facts

Lead sponsor	Knopp Biosciences
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	194
Start date	9 April 2008
Primary completion	31 July 2009
Estimated completion	4 September 2009
Sites	21 locations across United States

Drugs / interventions tested

Placebo
Dexpramipexole 50 mg/day — full drug profile →
Dexpramipexole 150 mg/day — full drug profile →
Dexpramipexole 300 mg/day — full drug profile →

Conditions studied

Amyotrophic Lateral Sclerosis — all drugs for Amyotrophic Lateral Sclerosis →

Sponsor

Knopp Biosciences — full company profile →

Who can join

Adults 21 to 80, any sex, with Amyotrophic Lateral Sclerosis. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Part 1: Number of Participants With Potentially Clinically Significant Hematology Results by Treatment Group Primary · 12 weeks

Number of Participants with Potentially Clinically Significant Hematology Results by Treatment Group. Percentages based on number of patients with at least one non-missing post-baseline value in each treatment group. Patients are only counted once per criterion per laboratory test.

White Blood Cell Count (x10^3/uL) < 2000/uL

Group	Value	95% CI
Placebo	0
50 mg/Day	0
150 mg/Day	0
300 mg/Day	0

Neutrophils (x10^3/uL) < 1000/uL

Group	Value	95% CI
Placebo	0
50 mg/Day	0
150 mg/Day	0
300 mg/Day	0

Eosinophils (x10^3/uL) > 5000/uL

Group	Value	95% CI
Placebo	0
50 mg/Day	0
150 mg/Day	0
300 mg/Day	0

Hemoglobin (g/dL) < 8 g/dL

Group	Value	95% CI
Placebo	0
50 mg/Day	0
150 mg/Day	0
300 mg/Day	0

Platelets (x10^3/uL) < 50,000/uL

Group	Value	95% CI
Placebo	0
50 mg/Day	0
150 mg/Day	0
300 mg/Day	0

Part 1: Number of Participants With Potentially Clinically Significant Blood Chemistry Results by Treatment Group Primary · 12 weeks

Number of Participants with Potentially Clinically Significant Blood Chemistry Results by Treatment Group. Percentages based on number of patients with at least one non-missing post-baseline value in each treatment group. Patients are only counted once per criterion per laboratory test.

Creatine Kinase (U/L) >= 10xULN

Group	Value	95% CI
Placebo	0
50 mg/Day	0
150 mg/Day	0
300 mg/Day	1

Total Bilirubin (mg/dL) > 1.5xULN

Group	Value	95% CI
Placebo	0
50 mg/Day	0
150 mg/Day	0
300 mg/Day	0

ALT (SGPT) (U/L) > 3xULN

Group	Value	95% CI
Placebo	0
50 mg/Day	0
150 mg/Day	0
300 mg/Day	2

AST (SGOT) (U/L) > 3xULN

Group	Value	95% CI
Placebo	0
50 mg/Day	0
150 mg/Day	0
300 mg/Day	1

Alkaline Phosphatase (U/L) > 1.5xULN

Group	Value	95% CI
Placebo	0
50 mg/Day	0
150 mg/Day	0
300 mg/Day	1

BUN (mg/dL) > 5xULN

Group	Value	95% CI
Placebo	0
50 mg/Day	0
150 mg/Day	0
300 mg/Day	0

Creatinine (mg/dL) > 3xULN

Group	Value	95% CI
Placebo	0
50 mg/Day	0
150 mg/Day	0
300 mg/Day	0

Sodium (mEq/L) low < 123 mEq/L

Group	Value	95% CI
Placebo	0
50 mg/Day	0
150 mg/Day	0
300 mg/Day	0

Part 1: Number of Participants With Treatment Emergent Potentially Clinically Significant Electrocardiogram (ECG) Findings by Treatment Group Primary · 12 weeks

Number of Participants with Treatment Emergent Potentially Clinically Significant Electrocardiogram (ECG) Findings by Treatment Group. Percentages are based on the number of patients with at least one non-missing post-baseline value in each treatment group.

Rhythm Sinus Tachycardia > 120 bpm

Group	Value	95% CI
Placebo	0
50 mg/Day	0
150 mg/Day	0
300 mg/Day	0

Rhythm Sinus Bradycardia < 40 bpm

Group	Value	95% CI
Placebo	0
50 mg/Day	0
150 mg/Day	0
300 mg/Day	0

Rhythm Sinus Block/Sinus Arrest

Group	Value	95% CI
Placebo	0
50 mg/Day	0
150 mg/Day	0
300 mg/Day	0

Rhythm Junctional Rhythm

Group	Value	95% CI
Placebo	0
50 mg/Day	0
150 mg/Day	0
300 mg/Day	0

Rhythm Atrial Flutter

Group	Value	95% CI
Placebo	0
50 mg/Day	0
150 mg/Day	0
300 mg/Day	0

Rhythm Atrial Fibrillation

Group	Value	95% CI
Placebo	0
50 mg/Day	0
150 mg/Day	0
300 mg/Day	1

Rhythm Supraventricular

Group	Value	95% CI
Placebo	0
50 mg/Day	0
150 mg/Day	0
300 mg/Day	0

Rhythm Tachycardia > 100 bpm

Group	Value	95% CI
Placebo	0
50 mg/Day	0
150 mg/Day	0
300 mg/Day	0

Part 1: Number of Participants With Potentially Clinically Significant Vital Sign Measurements by Treatment Group Primary · 12 weeks

Number of Participants with Potentially Clinically Significant Vital Sign Measurements by Treatment Group. Percentages are based on the number of patients with at least one non-missing post-baseline value in each treatment group.

Systolic Blood Pressure Increase of > 20 mmHg from baseline and >= 180mmHg

Group	Value	95% CI
Placebo	0
50 mg/Day	2
150 mg/Day	0
300 mg/Day	0

Systolic Blood Pressure Decrease of < -20 mmHg from baseline and <= 90 mmHg

Group	Value	95% CI
Placebo	2
50 mg/Day	0
150 mg/Day	0
300 mg/Day	0

Diastolic Blood Pressure Increase of > 15 mmHg from baseline and >= 105 mmHg

Group	Value	95% CI
Placebo	0
50 mg/Day	1
150 mg/Day	0
300 mg/Day	0

Diastolic Blood Pressure Decrease of < -15 mmHg from baseline and <= 50 mmHg

Group	Value	95% CI
Placebo	1
50 mg/Day	1
150 mg/Day	0
300 mg/Day	0

Pulse Increase of > 15 bpm from baseline and >= 120

Group	Value	95% CI
Placebo	0
50 mg/Day	1
150 mg/Day	0
300 mg/Day	0

Pulse Decrease of < -15 bpm from baseline and <= 50

Group	Value	95% CI
Placebo	0
50 mg/Day	0
150 mg/Day	0
300 mg/Day	1

Body Weight Increase of > 7% lbs from baseline

Group	Value	95% CI
Placebo	0
50 mg/Day	0
150 mg/Day	0
300 mg/Day	0

Body Weight Decrease of < -7% lbs from baseline

Group	Value	95% CI
Placebo	3
50 mg/Day	2
150 mg/Day	0
300 mg/Day	1

Part 1: Slope of ALSFRS-R (ALS Functional Rating Scale With Respiratory Component) From Baseline to Week 12 by Treatment Group Secondary · 12 weeks

The ALSFRS-R (ALS functional rating scale with respiratory component) is a validated scale which measures 4 functional domains, comprising respiratory function, bulbar function, gross motor skills, and fine motor skills. There are a total of 12 questions, each scored from 0 to 4 for a total possible score of 48, with higher scores representing better function. Slope is calculated using a linear mixed effects model with x-axis time in months and y-axis ALSFRS-R score. Units for slope are change per month in units on the ALSFRS-R scale.

Group	Value	95% CI
Placebo	-1.278	-1.82 – -0.74
Dexpramipexole (50 mg/Day)	-1.885	-2.48 – -1.29
Dexpramipexole (150 mg/Day)	-1.165	-1.71 – -0.62
Dexpramipexole (300 mg/Day)	-0.878	-1.44 – -0.31

Part 1: Slope of Upright Vital Capacity From Baseline to Week 12 by Treatment Group Secondary · 12 weeks

Slope of change in Upright Vital Capacity (percent predicted upright vital capacity) from Baseline to Week 12. A negative change/slope indicates clinical worsening. Slope is calculated using a linear mixed effects model with x-axis time in months and y-axis as percent predicted upright vital capacity. Units for slope are change per month in percent predicted upright vital capacity.

Group	Value	95% CI
Placebo	-4.398	-6.42 – -2.38
Dexpramipexole (50 mg/Day)	-4.003	-6.23 – -1.77
Dexpramipexole (150 mg/Day)	-2.389	-4.44 – -0.34
Dexpramipexole (300 mg/Day)	-3.947	-6.07 – -1.82

Part 2 Placebo Washout: Number of Participants With Potentially Clinically Significant Hematology Secondary · 4 weeks

White Blood Cell Count (x10^3/uL) < 2000/uL

Group	Value	95% CI
Placebo	0

Neutrophils (x10^3/uL) < 1000/uL

Group	Value	95% CI
Placebo	0

Eosinophils (x10^3/uL) > 5000/uL

Group	Value	95% CI
Placebo	0

Hemoglobin (g/dL) < 8 g/dL

Group	Value	95% CI
Placebo	0

Platelets (x10^3/uL) < 50,000/uL

Group	Value	95% CI
Placebo	0

Part 2 Placebo Washout: Number of Participants With Potentially Clinically Significant Blood Chemistry Results Secondary · 4 weeks

Creatine Kinase (U/L) >= 10xULN

Group	Value	95% CI
Placebo	0

Total Bilirubin (mg/dL) > 1.5xULN

Group	Value	95% CI
Placebo	0

ALT (SGPT) (U/L) > 3xULN

Group	Value	95% CI
Placebo	0

AST (SGOT) (U/L) > 3xULN

Group	Value	95% CI
Placebo	0

Alkaline Phosphatase (U/L) > 1.5xULN

Group	Value	95% CI
Placebo	0

BUN (mg/dL) > 5xULN

Group	Value	95% CI
Placebo	0

Creatinine (mg/dL) > 3xULN

Group	Value	95% CI
Placebo	0

Sodium (mEq/L) low < 123 mEq/L

Group	Value	95% CI
Placebo	0

Part 2 Placebo Washout: Number of Participants With Treatment Emergent Potentially Clinically Significant Electrocardiogram (ECG) Findings Secondary · 4 weeks

Rhythm Sinus Tachycardia > 120 bpm

Group	Value	95% CI
Placebo	0

Rhythm Sinus Bradycardia < 40 bpm

Group	Value	95% CI
Placebo	0

Rhythm Sinus Block/Sinus Arrest

Group	Value	95% CI
Placebo	0

Rhythm Junctional Rhythm

Group	Value	95% CI
Placebo	0

Rhythm Atrial Flutter

Group	Value	95% CI
Placebo	0

Rhythm Atrial Fibrillation

Group	Value	95% CI
Placebo	0

Rhythm Supraventricular

Group	Value	95% CI
Placebo	0

Rhythm Tachycardia > 100 bpm

Group	Value	95% CI
Placebo	0

Part 2 Placebo Washout: Number of Participants With Potentially Clinically Significant Vital Sign Measurements Secondary · 4 weeks

Systolic Blood Pressure Increase of > 20 mmHg from baseline and >= 180mmHg

Group	Value	95% CI
Placebo	0

Systolic Blood Pressure Decrease of < -20 mmHg from baseline and <= 90 mmHg

Group	Value	95% CI
Placebo	0

Diastolic Blood Pressure Increase of > 15 mmHg from baseline and >= 105 mmHg

Group	Value	95% CI
Placebo	2

Diastolic Blood Pressure Decrease of < -15 mmHg from baseline and <= 50 mmHg

Group	Value	95% CI
Placebo	0

Pulse Increase of > 15 bpm from baseline and >= 120

Group	Value	95% CI
Placebo	1

Pulse Decrease of < -15 bpm from baseline and <= 50

Group	Value	95% CI
Placebo	1

Body Weight Increase of > 7% lbs from baseline

Group	Value	95% CI
Placebo	0

Body Weight Decrease of < -7% lbs from baseline

Group	Value	95% CI
Placebo	0

Part 2 Placebo Washout: Absolute Change in ALSFRS-R Total Score Secondary · 4 weeks

The ALSFRS-R (ALS functional rating scale with respiratory component) is a validated scale which measures 4 functional domains, comprising respiratory function, bulbar function, gross motor skills, and fine motor skills. There are a total of 12 questions, each scored from 0 to 4 for a total possible score of 48, with higher scores representing better function. Units are points on the ALSFRS-R score as an absolute change from the baseline of the placebo washout to week 4 of the placebo washout.

Group	Value	95% CI
Placebo	-1.2	± 0.27

Part 2 Placebo Washout: Absolute Change in Upright Vital Capacity (Percent Predicted) From Baseline to End of Placebo Washout (Week 4) Secondary · 4 weeks

Absolute change in Upright Vital Capacity From Baseline to Week 4. Units are percent of predicted Upright Vital Capacity. A negative change indicates clinical worsening.

Group	Value	95% CI
Placebo	-3.1	± 0.95

Adverse events — posted to ClinicalTrials.gov

Time frame: Part 1: up to 12 weeks; Part 2 Placebo washout: up to 4 weeks; Part 2 Treatment period: up to 18 months. Reporting threshold: 5%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Part 1: Placebo

Serious: 0/27 (0%)

Deaths: 0/27

Part 1: Dexpramipexole (50 mg/Day)

Serious: 2/23 (9%)

Deaths: 0/23

Part 1: Dexpramipexole (150 mg/Day)

Serious: 0/26 (0%)

Deaths: 0/26

Part 1: Dexpramipexole (300 mg/Day)

Serious: 3/26 (12%)

Deaths: 0/26

Part 2: Placebo Washout

Serious: 5/97 (5%)

Deaths: 3/97

Part 2: Dexpramipexole (50 mg/Day)

Serious: 14/48 (29%)

Deaths: 15/48

Part 2: Dexpramipexole (300 mg/Day)

Serious: 12/44 (27%)

Deaths: 9/44

Serious adverse events (32 terms)

Reaction	System	Part 1: Placebo	Part 1: Dexpramipexole (50…	Part 1: Dexpramipexole (15…	Part 1: Dexpramipexole (30…	Part 2: Placebo Washout	Part 2: Dexpramipexole (50…	Part 2: Dexpramipexole (30…
RESPIRATORY FAILURE	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—	—
DYSPNOEA	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—	—
DISEASE PROGRESSION	General disorders	—	—	—	—	—	—	—
PNEUMONIA	Infections and infestations	—	—	—	—	—	—	—
HUMERUS FRACTURE	Injury, poisoning and procedural complications	—	—	—	—	—	—	—
DEEP VEIN THROMBOSIS	Vascular disorders	—	—	—	—	—	—	—
PULMONARY EMBOLISM	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—	—
INTESTINAL INFARCTION	Gastrointestinal disorders	—	—	—	—	—	—	—
ATRIAL FIBRILLATION	Cardiac disorders	—	—	—	—	—	—	—
URETHRAL OBSTRUCTION	Renal and urinary disorders	—	—	—	—	—	—	—
URINARY RETENTION	Renal and urinary disorders	—	—	—	—	—	—	—
NEUTROPENIA	Blood and lymphatic system disorders	—	—	—	—	—	—	—
ACUTE MYOCARDIAL INFARCTION	Cardiac disorders	—	—	—	—	—	—	—
CARDIAC FAILURE CONGESTIVE	Cardiac disorders	—	—	—	—	—	—	—
VERTIGO POSITIONAL	Ear and labyrinth disorders	—	—	—	—	—	—	—
ILEUS	Gastrointestinal disorders	—	—	—	—	—	—	—
NAUSEA	Gastrointestinal disorders	—	—	—	—	—	—	—
PANCREATITIS	Gastrointestinal disorders	—	—	—	—	—	—	—
SUDDEN DEATH	General disorders	—	—	—	—	—	—	—
CHOLECYSTITIS ACUTE	Hepatobiliary disorders	—	—	—	—	—	—	—
PNEUMONIA BACTERIAL	Infections and infestations	—	—	—	—	—	—	—
VIRAL INFECTION	Infections and infestations	—	—	—	—	—	—	—
CONCUSSION	Injury, poisoning and procedural complications	—	—	—	—	—	—	—
FALL	Injury, poisoning and procedural complications	—	—	—	—	—	—	—
SUBDURAL HAEMATOMA	Injury, poisoning and procedural complications	—	—	—	—	—	—	—

Other adverse events (45 terms — click to expand)

Reaction	System	Part 1: Placebo	Part 1: Dexpramipexole (50…	Part 1: Dexpramipexole (15…	Part 1: Dexpramipexole (30…	Part 2: Placebo Washout	Part 2: Dexpramipexole (50…	Part 2: Dexpramipexole (30…
Muscular Weakness	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—	—
Fall	Injury, poisoning and procedural complications	—	—	—	—	—	—	—
Constipation	Gastrointestinal disorders	—	—	—	—	—	—	—
Insomnia	Psychiatric disorders	—	—	—	—	—	—	—
Salivary Hypersecretion	Gastrointestinal disorders	—	—	—	—	—	—	—
Depression	Psychiatric disorders	—	—	—	—	—	—	—
Dry Mouth	Gastrointestinal disorders	—	—	—	—	—	—	—
Dysphagia	Gastrointestinal disorders	—	—	—	—	—	—	—
Post Lumbar Puncture Syndrome	Injury, poisoning and procedural complications	—	—	—	—	—	—	—
Urinary Tract Infection	Infections and infestations	—	—	—	—	—	—	—
Headache	Nervous system disorders	—	—	—	—	—	—	—
Anxiety	Psychiatric disorders	—	—	—	—	—	—	—
Cough	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—	—
Dyspnoea	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—	—
Nausea	Gastrointestinal disorders	—	—	—	—	—	—	—
Sinusitis	Infections and infestations	—	—	—	—	—	—	—
Upper Respiratory Tract Infection	Infections and infestations	—	—	—	—	—	—	—
Dysarthria	Nervous system disorders	—	—	—	—	—	—	—
Muscle Spasticity	Nervous system disorders	—	—	—	—	—	—	—
Tachycardia	Cardiac disorders	—	—	—	—	—	—	—
Diarrhoea	Gastrointestinal disorders	—	—	—	—	—	—	—
Oedema Peripheral	General disorders	—	—	—	—	—	—	—
Pyrexia	General disorders	—	—	—	—	—	—	—
Pneumonia	Infections and infestations	—	—	—	—	—	—	—
Neck Pain	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—	—
Pain In Extremity	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—	—
Pharyngolaryngeal Pain	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—	—
Respiratory Failure	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—	—
Rash	Skin and subcutaneous tissue disorders	—	—	—	—	—	—	—
Vomiting	Gastrointestinal disorders	—	—	—	—	—	—	—
Disease Progression	General disorders	—	—	—	—	—	—	—
Fatigue	General disorders	—	—	—	—	—	—	—
Contusion	Injury, poisoning and procedural complications	—	—	—	—	—	—	—
Dehydration	Metabolism and nutrition disorders	—	—	—	—	—	—	—
Hyperglycaemia	Metabolism and nutrition disorders	—	—	—	—	—	—	—
Arthralgia	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—	—
Back Pain	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—	—
Muscle Spasms	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—	—
Musculoskeletal Pain	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—	—
Myalgia	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—	—

Most-reported serious reactions: RESPIRATORY FAILURE, DYSPNOEA, DISEASE PROGRESSION, PNEUMONIA, HUMERUS FRACTURE, DEEP VEIN THROMBOSIS, PULMONARY EMBOLISM, INTESTINAL INFARCTION.

Data from ClinicalTrials.gov NCT00647296 adverse events section.

Sponsor's own description

This was a 2-part study of dexpramipexole in patients with ALS. Part 1 was a randomized, placebo-controlled, multi-center study to evaluate the safety, tolerability, and clinical effects of oral administration of 3 dosage levels of dexpramipexole vs. placebo for 12 weeks. Part 2 was a randomized, double-blind, 2-arm, parallel group, extension study evaluating the safety, tolerability, and clinical effects of oral administration of 2 dosage levels of dexpramipexole for up to 72 weeks.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Insights into the Pathogenesis of Neurodegenerative Diseases: Focus on Mitochondrial Dysfunction and Oxidative Stress.
Jurcau A. · · 2021 · cited 89× · PMID 34769277 · DOI 10.3390/ijms222111847
Neuro-Immune Crosstalk: Molecular Mechanisms, Biological Functions, Diseases, and Therapeutic Targets.
Guo X, Liu H, Song YJ, Wang JH, et al · · 2026 · cited 2× · PMID 41583906 · DOI 10.1002/mco2.70497

Verify or expand the search:

Other recruiting trials for Amyotrophic Lateral Sclerosis

Currently open trials in the same condition.

NCT07502677 — Diagnostic Accuracy of SleepImage Technology for Detecting Respiratory Failure in Patients With Amyotrophic Lateral Scle · recruiting
NCT07478172 — Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease · NA · recruiting
NCT07204977 — Acamprosate in C9orf72 Hexanucleotide Repeat Expansion Amyotrophic Lateral Sclerosis (ACALS) · Phase 1 · active not recruiting
NCT07290062 — A Study to Investigate the Safety and Pharmacodynamics of a Single Intrathecal Injection (IT) of INS1202 in Participants · Phase 1 · recruiting
NCT07259980 — A Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Participants With Superoxide Dismutase 1 (SOD- · recruiting

Other Knopp Biosciences trials

Trials by the same sponsor.

NCT04046939 — Dexpramipexole Dose-Ranging Biomarker Study in Subjects With Eosinophilic Asthma · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00647296 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Knopp Biosciences
Last refreshed: 8 July 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00647296.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing